metformin has been researched along with Peripheral Arterial Disease in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Peripheral Arterial Disease: Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One thousand sixty-four limbs in 1204 patients were identified (147 metformin, 196 other hypoglycemics [OH], 216 insulin, and 645 nondiabetics (nondiabetes mellitus [DM])." | 7.91 | Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. ( Cherr, GS; Dosluoglu, HH; Dryjski, ML; Harris, LM; Khan, SZ; Nader, ND; Rivero, M, 2019) |
| "One thousand sixty-four limbs in 1204 patients were identified (147 metformin, 196 other hypoglycemics [OH], 216 insulin, and 645 nondiabetics (nondiabetes mellitus [DM])." | 3.91 | Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. ( Cherr, GS; Dosluoglu, HH; Dryjski, ML; Harris, LM; Khan, SZ; Nader, ND; Rivero, M, 2019) |
| "Patients with type 2 diabetes mellitus (T2DM) are particularly at risk of developing major adverse cardiovascular events (MACE) and peripheral artery disease (PAD) due to an acceleration of the atherosclerotic process linked to hyperglycemia and inflammation with a greater risk of local complications." | 1.91 | Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin. ( Arnoux, A; Detriche, G; Galloula, A; Goudot, G; Khider, L; Maissoro, H; Messas, E; Mirault, T; Mohamedi, N; Poenou, G; Tan, S; Tran, Y, 2023) |
| "Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0." | 1.46 | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. ( Aubert, CE; Bourron, O; Cluzel, P; Hartemann, A; Kamel, S; Kemel, S; Lalau, JD; Lenglet, A; Liabeuf, S; Mary, A; Massy, ZA; Mentaverri, R; Salem, JE, 2017) |
| "In the restenosis group, there was a significantly higher percentage of patients taking metformin (p < 0." | 1.43 | Optimal blood pressure in patients with peripheral artery disease following endovascular therapy. ( Hasegawa, K; Hata, S; Moniwa, N; Sasaki, H; Takizawa, H; Tanaka, S; Ura, N, 2016) |
| "Metformin is recommended in type 2 diabetes mellitus because it reduced mortality among overweight participants in the United Kingdom Prospective Diabetes Study when used mainly as a means of primary prevention." | 1.36 | Metformin use and mortality among patients with diabetes and atherothrombosis. ( Bhatt, DL; Goto, S; Marre, M; Pasquet, B; Porath, A; Ravaud, P; Roussel, R; Smith, SC; Steg, PG; Travert, F; Wilson, PW, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, S | 3 |
| Goudot, G | 3 |
| Arnoux, A | 3 |
| Tran, Y | 3 |
| Maissoro, H | 3 |
| Poenou, G | 3 |
| Detriche, G | 3 |
| Khider, L | 3 |
| Mohamedi, N | 3 |
| Mirault, T | 3 |
| Galloula, A | 3 |
| Messas, E | 3 |
| Reitz, KM | 1 |
| Althouse, AD | 1 |
| Forman, DE | 1 |
| Zuckerbraun, BS | 1 |
| Vodovotz, Y | 1 |
| Zamora, R | 1 |
| Raffai, RL | 1 |
| Hall, DE | 1 |
| Tzeng, E | 1 |
| Khan, SZ | 1 |
| Rivero, M | 1 |
| Nader, ND | 1 |
| Cherr, GS | 1 |
| Harris, LM | 1 |
| Dryjski, ML | 1 |
| Dosluoglu, HH | 1 |
| Kibrik, P | 1 |
| Alsheekh, A | 1 |
| Izakovich, T | 1 |
| Chait, J | 1 |
| Goldstein, MA | 1 |
| Monteleone, CM | 1 |
| Hingorani, A | 1 |
| Ascher, E | 1 |
| Sasaki, H | 1 |
| Ura, N | 1 |
| Hata, S | 1 |
| Moniwa, N | 1 |
| Hasegawa, K | 1 |
| Takizawa, H | 1 |
| Tanaka, S | 1 |
| Mary, A | 1 |
| Hartemann, A | 1 |
| Liabeuf, S | 1 |
| Aubert, CE | 1 |
| Kemel, S | 1 |
| Salem, JE | 1 |
| Cluzel, P | 1 |
| Lenglet, A | 1 |
| Massy, ZA | 1 |
| Lalau, JD | 1 |
| Mentaverri, R | 1 |
| Bourron, O | 1 |
| Kamel, S | 1 |
| Roussel, R | 1 |
| Travert, F | 1 |
| Pasquet, B | 1 |
| Wilson, PW | 1 |
| Smith, SC | 1 |
| Goto, S | 1 |
| Ravaud, P | 1 |
| Marre, M | 1 |
| Porath, A | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Eurich, DT | 1 |
| Majumdar, SR | 1 |
| McAlister, FA | 1 |
| Tsuyuki, RT | 1 |
| Johnson, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metformin and Peripheral Arterial Disease
| Article | Year |
|---|---|
MetfOrmin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC): randomized clinical trial protocol.
Topics: Diabetes Mellitus, Type 2; Humans; Intermittent Claudication; Lower Extremity; Metformin; Peripheral | 2023 |
7 other studies available for metformin and Peripheral Arterial Disease
| Article | Year |
|---|---|
Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin.
Topics: Diabetes Mellitus, Type 2; Humans; Lower Extremity; Metformin; Peripheral Arterial Disease; Prospect | 2023 |
Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin.
Topics: Diabetes Mellitus, Type 2; Humans; Lower Extremity; Metformin; Peripheral Arterial Disease; Prospect | 2023 |
Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin.
Topics: Diabetes Mellitus, Type 2; Humans; Lower Extremity; Metformin; Peripheral Arterial Disease; Prospect | 2023 |
Occurrence of Major Local Lower Limb Events in Type 2 Diabetic Patients with Lower Extremity Arterial Disease: Impact of Metformin.
Topics: Diabetes Mellitus, Type 2; Humans; Lower Extremity; Metformin; Peripheral Arterial Disease; Prospect | 2023 |
Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Chronic Disease; Comorbidity; Diabetes Mellitus; Endo | 2019 |
Does Metformin Have an Effect on Stent Patency Rates.
Topics: Aged; Constriction, Pathologic; Diabetes Mellitus, Type 2; Endovascular Procedures; Female; Femoral | 2019 |
Optimal blood pressure in patients with peripheral artery disease following endovascular therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Ankle Brachial Index; Blood Pressure; Blood Pressure | 2016 |
Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
Topics: Aged; Chi-Square Distribution; Computed Tomography Angiography; Cross-Sectional Studies; Diabetes Me | 2017 |
Metformin use and mortality among patients with diabetes and atherothrombosis.
Topics: Age Factors; Aged; Aged, 80 and over; Cerebrovascular Disorders; Coronary Artery Disease; Creatinine | 2010 |
Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.
Topics: Canada; Cerebrovascular Disorders; Contraindications; Coronary Artery Disease; Diabetes Mellitus, Ty | 2011 |